An Observational, Non-Interventional Trial to Assess Patient Satisfaction and Safety of Subsys (TM) Spray Compared to Actiq (RM) for the Management of Breakthrough Pain in Chronic Pain Patients.

Trial Profile

An Observational, Non-Interventional Trial to Assess Patient Satisfaction and Safety of Subsys (TM) Spray Compared to Actiq (RM) for the Management of Breakthrough Pain in Chronic Pain Patients.

Discontinued
Phase of Trial: Phase IV

Latest Information Update: 10 Sep 2014

At a glance

  • Drugs Fentanyl (Primary)
  • Indications Cancer pain
  • Focus Therapeutic Use
  • Most Recent Events

    • 10 Sep 2014 Status changed from active, no longer recruiting to discontinued.
    • 16 Aug 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov registry record.
    • 27 Jul 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top